Method for the diagnosis, prognosis and treatment of prostate cancer metastasis
The present invention relates to a method for the diagnosis or the prognosis of metastasis, relapse or recurrence in prostate cancer which comprises determining if the c-MAF gene is amplified in a primary tumor sample. Likewise, the invention also relates to a method for the diagnosis or the prognosis of metastasis, relapse or recurrence in prostate cancer, as well as to a method for determining the tendency to develop bone metastasis with respect to metastasis in other organs, which comprise determining the c-MAF expression level. Finally, the invention relates to the use of a c-MAF inhibitor as therapeutic target for treating the prostate cancer.
1. An in vitro method for designing a customized therapy for a subject with prostate cancer, comprising:
(i) contacting a prostate tumor sample from the subject with an antibody to quantify c-MAF expression level, and
(ii) comparing the expression level obtained in (i) with the expression level of the c-MAF in a control sample,
wherein the antibody comprises a heavy chain CDR1 of SEQ ID NO: 21, a heavy chain CDR2 of SEQ ID NO: 22, a heavy chain CDR3 of SEQ ID NO: 23, a light chain CDR1 of SEQ ID NO: 18, a light chain CDR2 of SEQ ID NO: 19, and a light chain CDR3 of SEQ ID NO: 20,
wherein if the expression level of the c-MAF in the tumor sample is increased with respect to the expression level of the c-MAF in the control sample, then said subject is susceptible to receive clodronate.
2. The method of claim 1 , wherein the increase of c-MAF expression is at least about 1.1 times, 1.2 times, 1.3 times, 1.4 times, 1.5 times, 2 times, 3 times, 4 times, 5 times, 10 times, 20 times, 30 times, 40 times, 50 times, 60 times, 70 times, 80 times, 90 times, 100 times or greater than the control sample.
3. The method of claim 1 , wherein the expression level is measured using Western blot, ELISA, immunohistochemistry or a protein array.
4. A method for treating, inhibiting, reducing the risk of and/or preventing bone metastasis, relapse or recurrence from prostate cancer in a subject suffering prostate cancer, comprising:
(i) contacting a prostate tumor sample from the subject with an antibody to quantify c-MAF expression level,
(ii) comparing the expression level obtained in (i) with the expression level of the c-MAF in a control sample, wherein if the expression level or the c-MAF in the tumor sample is increased with respect to the expression level of the c-MAF in the control sample, then the subject is susceptible to receive clodronate, and
(iii) administering clodronate to said subject,
wherein the antibody comprises a heavy chain CDR1 of SEQ ID NO: 21, a heavy chain CDR2 of SEQ ID NO: 22, a heavy chain CDR3 of SEQ ID NO: 23, a light chain CDR1 of SEQ ID NO: 18, a light chain CDR2 of SEQ ID NO: 19, and a light chain CDR3 of SEQ ID NO: 20.
5. The method of claim 4 , wherein the bone metastasis is osteolytic metastasis.
6. The method of claim 4 , wherein the increase of c-MAF expression is at least about 1.1 times, 1.2 times, 1.3 times, 1.4 times, 1.5 times, 2 times, 3 times, 4 times, 5 times, 10 times, 20 times, 30 times, 40 times, 50 times, 60 times, 70 times, 80 times, 90 times, 100 times or greater than the control sample.
7. The method of claim 4 , wherein the expression level is measured using Western blot, ELISA, immunohistochemistry or a protein array.
8. An in vitro method for diagnosing metastasis and/or recurrence in a subject with prostate cancer and/or an in vitro method for the prognosis of the tendency to develop metastasis and/or recurrence in a subject with prostate cancer and treating said subject, comprising:
(i) contacting a prostate tumor sample from the subject with an antibody to quantify c-MAF expression level, and
(ii) comparing the expression level obtained in (i) with the expression level of the c-MAF in a control sample,
wherein the antibody comprises a heavy chain CDR1 of SEQ ID NO: 21, a heavy chain CDR2 of SEQ ID NO: 22, a heavy chain CDR3 of SEQ ID NO: 23, a light chain CDR1 of SEQ ID NO: 18, a light chain CDR2 of SEQ ID NO: 19, and a light chain CDR3 of SEQ ID NO: 20,
wherein if the expression level of the c-MAF in said tumor sample is increased with respect to the expression level of the c-MAF in the control sample, then said subject has a positive diagnosis for metastasis, relapse or recurrence or a greater tendency to develop metastasis, relapse or recurrence,
(iii) determining that the subject has an increase in the expression level of the c-MAF in the tumor sample with respect to the control sample, and
(iv) administering a therapeutically effective amount of clodronate to said subject.
9. The method of claim 8 , wherein the bone metastasis is osteolytic metastasis.
10. The method of claim 8 , wherein the increase of c-MAF expression is at least about 1.1 times, 1.2 times, 1.3 times, 1.4 times, 1.5 times, 2 times, 3 times, 4 times, 5 times, 10 times, 20 times, 30 times, 40 times, 50 times, 60 times, 70 times, 80 times, 90 times, 100 times or greater than the control sample.
11. The method of claim 8 , wherein the expression level is measured using Western blot, ELISA, immunohistochemistry or a protein array.